Global Sales of Epilepsy Drugs Market to Grow $5.35 billion by 2022 Says a New Report Available at

Share Article adds “PharmaPoint Epilepsy – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store. Hepatitis C Virus Market is expected to grow during the Forecast Period.

Market Research Report

Market Research Report and Industry Analysis Reports

Moderate Growth in the Epilepsy Market is Expected from 2012 to 2022

The global epilepsy market was valued at an estimated $4.2 billion in 2012. GlobalData expects the market to grow to $5.35 billion by 2022, with more than 50% of sales coming from the US. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction.

Major drivers of market growth over this forecast period will include:

  •     Introduction of novel antiepileptic drugs (AEDs) with higher prices in the US and European Union (EU)
  •     Introduction of the newer drugs into the Asian market, particularly in Japan
  •     Increasing access to epilepsy pharmacotherapy by the populations of India and China

Major barriers to the growth of the epilepsy market will include:

  •     A crowded marketplace, which currently comprises more than 20 AEDs, many of which are available in generic form, resulting in individual drugs struggling to distinguish themselves
  •     Concerns over decreasing healthcare costs as part of government austerity measures, which will impede market growth, particularly in Europe
  •     Generic erosion of branded drug sales following small-molecule patent and marketing exclusivity expiries, particularly affecting Vimpat (lacosamide) and Lyrica (pregabalin)

Complete Report Details Available at .

Key Questions Answered

  •     Even with more than 20 AEDs on the market, there are still ~20% refractory patients. Additional unmet needs still exists in terms of safety and efficacy. Will the drugs under development fulfil the unmet needs of the epilepsy market?
  •     Several brands of AEDs are due for patent expiry. How will the patent expiries impact the epilepsy therapeutics market?
  •     The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022?
  •     What governmental changes are likely to change the epilepsy treatment landscape in the markets researched? Which is the biggest growth market globally?

Key Findings

  •     New market entrants particularly Fycompa, Trobalt/Potiga and brivaracetam will increase competitiveness and cannibalize sales of existing AEDs.
  •     Drivers for market growth will include the introduction of the newer epilepsy drugs into the Asian market, particularly in Japan.
  •     Government cost-cutting measures will negatively impact epilepsy drug market in the EU

Order a Purchase Copy at .
(This is a premium report priced at US$10995 for a single user License.)

Company Profiles include in report:

  •     UCB
  •     Eisai
  •     Pfizer
  •     GlaxoSmithKline
  •     Novartis
  •     Abbott
  •     Dainippon Sumitomo Pharma

Companies Seek to Compete in a Crowded Epilepsy Market Through Novel Drug Developent, Strategic Licensing and Acquisitions, and Expansion into New Markets

  •     Historically, the epilepsy market has been dominated by gamma-aminobutyric acid (GABA) modulators and sodium channel blockers. The major players in the market have been Pfizer, which markets the sodium channel blocker Dilantin (phenytoin); Abbott (North America) and Sanofi (outside North America), which market sodium valproate, which primarily modulates GABA; and Novartis, which markets the sodium channel blockers Tegretol (carbamazepine) and Trileptal (oxcarbazepine).
  •     However, the 2000s saw a shift in dominance in the epilepsy drug market with the launch of third-generation AEDs that focused on novel targets as well as improved tolerability and efficacy. UCB’s Keppra (levetiracetam) and GlaxoSmithKline’s (GSK’s) Lamictal (lamotrigine) grew rapidly to blockbuster status and have replaced the older gold standards in most western markets as first-line treatments. Even though both Keppra and Lamictal have faced declining sales following generic entry, UCB and GSK will maintain their dominance in the market by expanding their exisiting drugs into new markets, particularly in Asia, as well as by launching new AEDs, such as Vimpat and brivaracetam (BRV) from UCB and Trobalt/Potiga (retigabine/ezogabine) from GSK.
  •     Eisai, a newcomer to the epilepsy market, is poised to become a key player during the forecast period through its offering of three AEDs acquired through licensing from other companies: Zonegran (zonisamide) from Elan, Zebinix (eslicarbazepine acetate) from Bial - Portela & CA, S.A., and Banzel/Inovelon (rufinamide) from Novartis, as well as its latest offering Fycompa (perampanel) which was developed in-house and has been recently approved in the US and EU.
  •     Current strategies for growth in the face of steep generic erosion following patent expiration have included reformulation of pivotal products and strategic acquisitions or partnerships to expand pipeline and marketed product portfolios. The market entry strategy for new drugs is based on initially seeking approval for drugs as adjunctive therapies in the refractory partial-seizure population, the patient segment with the greatest unmet need.

Explore more reports on Pharmaceuticals industry at .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
Follow >
Sandler Research
Like >
Follow us on
Visit website